A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Cimlanod (Primary) ; Nitroglycerin
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Oct 2018 Planned End Date changed from 5 Dec 2018 to 29 May 2019.
- 31 Oct 2018 Planned primary completion date changed from 4 Dec 2018 to 29 May 2019.
- 14 Feb 2018 Status changed from not yet recruiting to recruiting.